Idiopathic pulmonary fibrosis (IPF) is a deadly disease, largely unresponsive to treatment
with corticosteroids and immunosuppressives. The aim of this randomized, prospective …

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial pneumonia characterized
by a poor response to therapy and a dismal prognosis. Historically, the fibrotic process in IPF …

The clinical course of idiopathic pulmonary fibrosis (IPF) is variable; however, the long-term
survival in IPF is poor. Prednisone has been the mainstay of therapy since its release for …

The magnitude of treatment effect can be assessed by a number of methods. One method of
collectively analysing data is that used by the Cochrane Collaboration. Their systematic …

Interferon (IFN)-γ was recently proposed as a treatment for idiopathic pulmonary fibrosis. We
report on four patients who developed acute respiratory failure with new alveolar opacities …

Purpose: Chronic interstitial fibrosis (IPF) of the lung is best described by an ongoing
inflammatory process leading to permanent activation of lung fibroblasts which causes a …

Recently updated guidelines have provided revised recommendations, based on the
GRADE criteria, for the diagnosis and pharmacological and non-pharmacological …

Idiopathic pulmonary fibrosis is a chronic condition of the lung parenchyma involving
progressive injury, inflammation, and fibrosis. Data collected from October 1988 through …

The long-standing need to determine an effective medical treatment regimen with clinically
significant and relevant end-points to improve outcome for patients with idiopathic …

IPF is a rare lung disease that causes shortness of breath and low oxygen levels because of
lung scarring. There is no cure, but there are several medications used to treat IPF that help …